Skip to main content
6880 search results for:

Sulfonylurea 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 30-04-2024 | Gout | News | Article

    SGLT2 inhibitors show gout prevention benefit over sulfonylureas

    Indeed, the study’s secondary outcome of major adverse cardiovascular events was less common among patients in the SGLT2 inhibitor group than the sulfonylurea group, with 456 events compared with 503 in the sulfonylurea group over a mean follow-up of 1.4 and 1.3 years, respectively.

  2. Open Access 17-02-2024 | Glibenclamide | OriginalPaper

    A loss-of-function mutation in KCNJ11 causing sulfonylurea-sensitive diabetes in early adult life

    The central role of the ATP-sensitive potassium (K ATP ) channel in glucose-stimulated insulin secretion from pancreatic beta cells is well understood [ 1 ]. Glucose uptake and metabolism leads to an increase in the ATP/ADP concentration that …

  3. Open Access 05-12-2023 | Type 2 Diabetes | BriefCommunication

    Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas

    Type 2 diabetes, like many other multifactorial disorders, includes monogenic forms that are rare, more severe, and appear earlier in life than common polygenic forms [ 1 ]. Rare, pathogenic, bi-allelic variants in GLIS3 cause a severe syndrome …

  4. Open Access 01-12-2023 | Magnetic Resonance Imaging | OriginalPaper

    Abcc8 (sulfonylurea receptor-1) knockout mice exhibit reduced axonal injury, cytotoxic edema and cognitive dysfunction vs. wild-type in a cecal ligation and puncture model of sepsis

    Sepsis-associated brain injury (SABI) is characterized by an acute deterioration of mental status resulting in cognitive impairment and acquisition of new and persistent functional limitations in sepsis survivors. Previously, we reported that …

  5. Open Access 01-12-2023 | Sulfonylurea | OriginalPaper

    The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study

    Lower limb amputation (LLA) is a highly feared outcome of type 2 diabetes (T2D) [ 1 ]. LLAs not only have a profound impact on the patient’s life, but are also associated with great economic burden [ 2 ] and high mortality rates [ 3 ]. LLAs are …

  6. 19-04-2023 | Glimepiride | ReviewPaper

    Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach

    Sulfonylureas (SU) continue to be a vital therapeutic category of oral hypoglycemic agents (OHAs) for the management of type 2 diabetes mellitus (T2DM). Physicians consider modern SU (gliclazide and glimepiride) as “safe and smart” choices for …

  7. 03-10-2023 | Sulfonylurea | Online First

    Correction to: Trends in Use of Sulfonylurea Types Among US Adults with Diabetes: NHANES 1999–2020

  8. 28-01-2023 | Sulfonylurea | OriginalPaper

    Association of ABCC8 gene variants with response to sulfonylurea in type 2 diabetes mellitus

    Diabetes mellitus (DM), as a metabolic disorder, is associated with high blood sugar (glucose) levels due to the inability to produce enough insulin and inefficient use of insulin [ 1 ]. Deficiency in insulin secretion and insulin resistance cause …

  9. Open Access 01-12-2022 | Glimepiride | OriginalPaper

    Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs

    Sulfonylureas (SUs) have been available for the treatment of type 2 diabetes for more than 50 years. These drugs are very effective at lowering glucose [ 1 ] and have a low cost for the healthcare system. Until now, the drug class is a viable …

  10. 11-10-2023 | Metformin | Online First

    Effect of metformin (vs. placebo or sulfonylurea) on all-cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta-analysis

    Diabetes is a common disease, and some drugs are prescribed to control this disease. Metformin is one of the diabetics’ drugs widely used in treating people with diabetes [ 1 ]. Metformin is one of the first-line oral anti-hyperglycemic factors. It …

  11. Open Access 01-08-2021 | Glimepiride | OriginalPaper

    Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas

    Since their inception in the commercial market in the mid-twentieth century, sulfonylureas (SUs) have remained a therapeutic option in the management of type 2 diabetes (T2D). Despite their established glucose-lowering effects, there is no …

  12. 01-06-2022 | Glibenclamide | OriginalPaper

    Early transition to sulfonylurea therapy in infant with DEND syndrome due to F132L ABCC8 mutation

    Heterozygous activating mutations in KCNJ11 and ABCC8 genes encoding, respectively, Kir6.2 and SUR1 subunits of the ATP-sensitive potassium (KATP) channels are the most common causes of permanent neonatal diabetes mellitus (PNDM) [ 1 ]. Some of …

  13. 01-07-2023 | Sulfonylurea | News

    Sulfonylurea-DPP-4 inhibitor combination: risk of hypoglycaemia similar for all combinations

  14. 01-12-2021 | Glimepiride | ReviewPaper

    Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review

    Type 2 diabetes (T2DM) is increasing worldwide [ 1 ]. According to the International Federation of Diabetes (IDF), 463 million people were affected by diabetes worldwide in 2019 and its prevalence is still increasing; estimated to reach 700 million …

  15. 11-01-2022 | Sulfonylurea

    KCNQ1 rs2237895 polymorphism is associated with the therapeutic response to sulfonylureas in Iranian type 2 diabetes mellitus patients

    Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that shows high heterogeneity. The most common traits among patients are insulin resistance besides β-cells dysfunction, which leads to hyperglycemia ( 1 ). Based on the International …

  16. Open Access 01-12-2023 | Sulfonylurea | OriginalPaper

    The use of metformin, sulfonylurea compounds and insulin and the risk of hip fractures in diabetic patients: a systematic review and meta-analysis of observational studies

    Recently, with the aging of the population, the increasing incidence of hip fractures has become a major health problem. It is estimated that by the middle of this century, more than 6 million people will suffer hip fractures yearly, including …

  17. 01-12-2021 | Sulfonylurea | OriginalPaper

    A pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients

    Diabetes is a chronic metabolic disease that is associated with elevated blood glucose levels and caused by genetic and environmental factors [ 1 ]. The global prevalence of diabetes is projected to reach 592 million by 2035 [ 2 – 4 ]. Diabetes …

  18. 11-01-2022 | Sulfonylurea

    Effects of the TCF7L2 and KCNQ1 common variant on sulfonylurea response in type 2 diabetes mellitus patients: a preliminary pharmacogenetic study

    Type 2 diabetes mellitus (T2DM) is a common chronic disease affected by genetic and environmental factors that cause patients to suffer from high blood glucose levels [ 1 ]. It was estimated that by 2015, 415 million people worldwide had type 2 …

  19. 01-01-2022 | Glimepiride | OriginalPaper

    Cross sectional study on proportion of sulfonylureas among various oral antidiabetic drugs using for Japanese patients with type 2 diabetes, analyzed from NSAID Study-2

    Most patients with type 2 diabetes mellitus (T2DM) require blood glucose-lowering therapy to improve glycemic control and reduce long-term complications. Based on evidence, the American Diabetes Association (ADA) and the European Association for …

  20. 24-04-2023 | Type 2 Diabetes | News | Article

    Sulfonylureas ‘unlikely’ to increase CV, mortality risk in real-world use

    Findings from a Scottish national cohort study show that the use of sulfonylureas as second-line glucose-lowering therapy is not associated with elevated cardiovascular risk or all-cause mortality.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.